Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2013

View Archived Issues

Pfizer develops novel ADCs targeting IL-13RA2

MRX-34 shows promising results in rodent and nonhuman primate models

Genentech presents preliminary safety and pharmacokinetic data for MPDL-3280A

Neuralgene set to begin animal studies of ALS gene therapy

BAY-94-9343 demonstrates clinical activity in patients with solid tumors

Matrix-Bio and Quest Diagnostics sign metabolomic biomarker licensing agreement

Novartis presents new data for their ALK inhibitor LDK-378

Oncos Therapeutics discloses novel cancer vaccines

Acorda Therapeutics reports phase II Ampyra study results in patients with post-stroke deficits

Hypermethylation of the HOXA4 gene as a potential biomarker in CML

FDA sets PDUFA action date for PA-21

New agents for tuberculosis prepared by CSIR

Merck & Co. presents new ROMK blockers for cardiovascular disorders

Phase I study of Mologen's MGN-1404 approved by Paul-Ehrlich Institute

Novel MAbs targeting human GITR prepared by Sanofi

Eli Lilly patents novel antibodies for lipoprotein disorders

Discovery Labs receives correspondence from FDA regarding updated Surfaxin specifications

Asmacure commences phase I/II trial of dry powder for inhalation of lead compound

New HIF-PH inhibitors synthesized by Merck & Co.

NeurOp receives second half of NIH grant for schizophrenia research

Board recommends continuation of enobosarm phase III trials

Merrimack updates progress of phase II HER2-negative breast cancer study

NeuroDerm studies levodopa/carbidopa patch pump in phase IIa study

Santaris and Bristol-Myers Squibb establish strategic alliance

BHR Pharma updates progress of SyNAPSe study in severe traumatic brain injury

Topline results from first pivotal COPD study of fixed-dose aclidinium/formoterol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...